iRhythm (IRTC) officer sells 4,027 shares to cover RSU taxes

Rhea-AI Filing Summary

iRhythm Holdings, Inc. reported that executive officer Minang Turakhia, its chief medical and scientific officer, executed open-market sales of a total of 4,027 shares of common stock on March 2, 2026 at prices around $128.45 per share. According to the footnote, these shares were sold specifically to cover tax withholding and remittance obligations arising from the vesting of restricted stock units. Following these transactions, Turakhia directly holds 54,906 shares of iRhythm common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turakhia Minang

(Last) (First) (Middle)

C/O IRHYTHM HOLDINGS, INC.

699 8TH ST #600

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iRhythm Holdings, Inc. [ IRTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MED/SCI OFCR EVP ADVTECH

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026	03/02/2026	S		1,487(1)	D	$128.445	57,446	D
Common Stock	03/02/2026	03/02/2026	S		1,310(1)	D	$128.446	56,136	D
Common Stock	03/02/2026	03/02/2026	S		1,230(1)	D	$128.453	54,906	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold to cover tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs).

Remarks:

	/s/ Marc Rosenbaum, attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did iRhythm (IRTC) report for Minang Turakhia?

iRhythm reported that executive Minang Turakhia sold 4,027 shares of common stock. The sales occurred on March 2, 2026 at prices around $128.45 per share and were tied to tax obligations from vesting restricted stock units.

Why did Minang Turakhia sell iRhythm (IRTC) shares in this Form 4 filing?

The shares were sold to cover tax withholding and remittance obligations triggered by vesting restricted stock units. This means the transactions were related to equity compensation taxation rather than a discretionary decision to reduce overall economic exposure.

How many iRhythm (IRTC) shares did Minang Turakhia sell and at what prices?

Minang Turakhia sold a total of 4,027 iRhythm common shares. The reported sales prices were approximately $128.445, $128.446, and $128.453 per share in three separate open-market transactions on March 2, 2026.

How many iRhythm (IRTC) shares does Minang Turakhia hold after these sales?

After completing the tax-related sales, Minang Turakhia directly holds 54,906 shares of iRhythm common stock. This post-transaction balance reflects all three reported open-market sales executed on March 2, 2026.

What role does Minang Turakhia hold at iRhythm (IRTC) in this Form 4?

Minang Turakhia is identified as an officer of iRhythm with the title chief medical and scientific officer and executive vice president of advanced technology. The Form 4 reports his personal open-market sales of company common stock related to RSU tax withholding.